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Summary (241 words) 
Determining the optimal frequency of replacement therapy is a clinically relevant issue in factor 
VII (FVII) deficiency, a bleeding disorder characterised by trace levels of a protein with a very 
short half-life. The main objective of this study was to clarify the discrepancy between the 
unfavourable PK data and positive clinical results obtained with rFVIIa. In Vivo Recovery (IVR) 
was determined in 56 patients using data from the Seven Treatment Evaluation Registry 
(STER) and a full PK analysis was performed in 10 severe FVII-deficient patients (FVII 
coagulant activity [FVII:C] <2%) in a non-bleeding state. When evaluated using FVII:C, the main 
study results were: i. low IVR (0.59 U dl-1/U kg-1), ii. a very large volume of distribution at steady 
state (14.72 dl kg-1), iii. fast clearance (4.41 dl h kg-1), iv. very short half-life (2.12 h) and mean 
residence time (MRT) (3.05 h). Significantly (p <0.001) longer half-life (5.80 h) and MRT (8.38 
hours) were obtained using a global assay, the Prothrombin Time ratio (PTr). The large volume 
of distribution of rFVIIa, approximately 40 times the plasma volume, the low IVR, the very short 
half-life and the fast clearance, indicate that a rapid and substantial diffusion towards the 
extravascular spaces occurs. The discrepancy between the FVII:C- and the PTr-related data 
indicate the presence of noticeable plasma clotting activity after rFVIIa infusion, when FVII:C is 
not detectable, consistent with the observation that prophylaxis is effective with less frequent 
administrations and low doses. 
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Introduction 
In congenital bleeding disorders (CBD), the mainstay for the prevention and treatment of 
bleeding episodes is replacement therapy (RT), the efficacy of which can be indirectly measured 
through pharmacokinetic (PK) methods based on the assessment of post-infusion factor levels 
over time (1). Specific clotting factor levels are currently considered the best determinants of 
haemostatic correction (1-3), and the key element for efficacy evaluation. Post-infusion clotting 
factor levels depend on RT dose and frequency as well as the PK profiles, which are factor 
specific. 
 
Currently, little information is available on the PK of activated factor VII (FVIIa) in FVII 
deficiency, a CBD with an estimated prevalence of one in 500,000 individuals (4-6) and 
characterised by large variation in residual FVII levels and clinical phenotypes. Treatment 
demands for FVII deficiency may vary considerably, ranging from episodic, infrequent factor 
administrations to high-dose substitutions for prophylaxis or major surgical interventions. These 
differences in treatment demands mostly depend on the clinical severity of the defect, which 
may vary from a mild, impaired primary haemostasis-like clinical picture to very severe, life-
threatening and invalidating forms (7, 8).  
 
 
Preliminary PK data on recombinant FVIIa (rFVIIa) in patients with FVII deficiency showed a fast 
clearance and very short half-life (9); more recent data demonstrated an increased volume of 
distribution (10). Notwithstanding the unfavourable PK data reported (9, 10), rFVIIa has been 
successfully used for prophylaxis in patients with FVII deficiency (11-14), both in young children 
and adults (14). Considering this apparent discrepancy, understanding the PK profile of rFVIIa 
in patients with FVII deficiency is of paramount importance.  
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To evaluate the decline of rFVIIa in the bloodstream, we studied its PK in patients with severe 
FVII deficiency and compared the ‘specific’ FVII coagulant activity (FVII:C) assay with a ‘global’ 
test, the Prothrombin Time ratio (PTr). Further, extensive in vivo recovery (IVR) evaluations 
were performed using data collected from a large number of patients treated with rFVIIa, 
obtained from the Seven Treatment Evaluation Registry (STER). 
 
Materials and methods 
Patients 
Two cohorts of patients received rFVIIa (NovoSeven®, Novo Nordisk A/S, Bagsværd, Denmark). 
The first consisted of 10 non-bleeding patients (6 females, 4 males; median age 43 years, range 
9–57 years) with severe FVII deficiency (FVII:C <2%). A complete PK evaluation was performed 
in these patients after an rFVIIa infusion (16–24 µg kg-1; mean 19.7, median 20 µg kg-1). The 
effect of rFVIIa on FVII:C and PTr assays was evaluated pre-dose and 0.17–24 hours (0.17, 
0.5, 1, 2, 4, 6, 8, 10 and 24 hours) post-dose (15) using a Non-Compartmental Analysis (NCA) 
(16-18). Doses of rFVIIa have been converted to IU according to the conversion factor 1 µg = 50 
IU, because the FVII:C concentration was expressed as IU/dl. To analyse the decay of the PTr 
data, inverse values (1/PTr) were used to graphically compare the data obtained using FVII:C 
and PTr; values were expressed as a percentage of the highest post-infusion value (Fig. 1). 
 
The second cohort comprised 56 patients (32 females, 24 males; median 23 years, range 2–81) 
from the multi-centre, prospective, observational, web-based STER (Clinicaltrials.gov identifier: 
NCT01269138), who required RT with rFVIIa (Table 1). Patients were selected on the basis of a 
cut-off of FVII:C levels of 26%, as levels higher than this threshold have an uncertain clinical 
relevance (19, 20). IVR was evaluated from plasma samples collected prior to and 15 minutes 
after RT with rFVIIa for prophylaxis, treatment of spontaneous bleeding episodes or surgical 
interventions. Patients with a FVII inhibitor were excluded from analyses. Only data obtained 
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using high-sensitivity thromboplastins (international sensitivity index [ISI] 1) were included in 
the IVR analyses to eliminate the influence of the thromboplastin ISI on the clotting assays.  
 
In vivo recovery  
Incremental IVR was calculated as the ratio between the post-infusion gain (15 minutes) of FVII 
and the amount of factor administered according to the following formula: 
IVR = MPIL  BL 
                   TDA 
where:  
IVR is expressed as U dl-1/U kg-1, MPIL is maximum post-infusion level (U dl-1), BL is baseline 
level (U dl-1) and TDA is total dose administered (U kg-1). 
 
Statistical analysis  
All NCA parameters were calculated using WinNonlin (Pharsight, Cary, NC, USA). Mean and 
standard deviation were used as position parameters to describe the variable distribution. 
Multivariate analysis was performed by running a generalised linear model with conditional 
gamma distribution and canonical link (21). This model was chosen because the continuous 
response variable (IVR) had non-normal distribution on the positive semi-axis with a significant 
skewness degree. The final model included sex (dichotomous variable), age (continuous 
variable) and severity (8). After running the full model with all interactions, variables found not to 
have a significant effect were removed from the model following a backwards selection criterion. 
The analyses were performed using R language version 2.15.2, an open-source programming 
language and software environment for statistical computing and graphics (www.r-project.com). 
 
Ethics 
Data on IVR evaluations were part of the STER, a study approved by the Internal Review 
Boards (IRBs) of L’Aquila University and all the centres participating in the study. The PK study 
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in 10 patients with a severe FVII deficiency administered rFVIIa in a non-bleeding state was 
approved by the IRB of the University Hospital in Bratislava and by the IRB of L’Aquila 
University (22/11/2011; comitato.etico@asl-laquila.it). 
 
Results 
IVR evaluations  
The IVR distribution following rFVIIa administration in the STER cohort showed a strong positive 
asymmetry, with values ranging from 0.03 to 2.1 U dl-1/U kg-1 (mean: 0.59; median: 0.46; SD: 
0.5). When subjects were grouped according to clinical severity, for major bleeders, significantly 
higher (p=0.04) IVR values were observed (Fig. 1). Multivariate analysis of the IVR data, which 
did not show an effect of age (p=0.17) or sex (p=0.41), indicated a significant influence of 
clinical severity. 
 
PK evaluation 
Data pertaining to PK parameters from the 10 non-bleeding patients with severe FVII deficiency 
are reported in Table 2. With reference to the dose-independent parameters, the PK data 
obtained using the FVII:C assay were significantly different from those obtained using the PTr 
assay (Table 2). A very good correlation of parameters over time was observed for both assays 
(Table 2); however, the decay of the 1/PTr curve was less biphasic than that of FVII:C (Fig. 2). 
Mean residence time (MRT), half-life and terminal half-life of the 1/PTr values were higher in 
comparison with the corresponding parameters obtained using FVII:C. 
 
Discussion 
Here we report the PK of rFVIIa in a large number of patients with severe FVII deficiency, 
representative of the whole clinical spectrum of FVII deficiency, with the majority of the cohort 
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(66.1%) accounting for symptomatic individuals and more than 20% with severe phenotypes 
(Table 1). 
 
We performed extensive IVR evaluations but despite attempts to reduce the IVR variability by 
restricting the analysis to assays performed with thromboplastins of similar sensitivity (ISI≅1), 
excluding inhibitor patients and further restricting the cohort to patients with FVII:C levels ≤26%, 
substantial variation still remained. This finding could not be explained by sex or age; in the 
multivariate analysis, the only significant determinant of IVR variability was disease severity, 
which somehow reflected residual FVII expressed by the mutated gene. It is tempting to 
speculate that the presence of native FVII molecules may influence IVR. All in all, we believe 
that the low rFVIIa recovery and its variability may mostly be accounted for by a large 
extravascular distribution volume of rFVIIa, a supposition supported by the finding that the 
rFVIIa volume of distribution at equilibrium (Vss) was approximately 40 times that of the normal 
plasma volume (Table 2).  
 
The full PK analysis preformed provided other relevant information including a low rFVIIa area 
under the curve (AUC), short half-life and fast clearance. In this respect it is worth noting that 
the terminal-phase half-life of rFVIIa appeared longer than what the MRT or half-life might have 
indicated. This finding, together with a prolonged pharmacodynamic effect, may be explained by 
a reduction in factor flow from the plasma pool to the extravascular space at the end of the 
decay curve, as indicated by the apparent volume of distribution, based on the terminal phase 
(Vz), being higher than the Vss. 
 
Mathijssen et al (12) described three cases of very severe FVII deficiency treated with rFVIIa 
prophylaxis in whom a very fast clearance together with very low AUC and t1/2 (0.51 hour) were 
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observed. Of note, prophylaxis was judged applicable, safe and clinically efficacious (12). The 
observations of this case report were considerably strengthened by our own experience with a 
large number of patients, which showed that prophylaxis schedules based on an average rFVIIa 
total dose of 100 µg kg-1 per week split into three administrations were efficacious (14). Such 
replacement regimens may be regarded as insufficient based on the PK data reported here and 
in the literature. A possible explanation for the efficacy of prophylaxis may be related to the 
binding of FVIIa to the perivascular sites (22) from where it would be slowly released. Another 
possibility is that excess rFVIIa may bind to the endothelial protein C receptor on undamaged 
endothelial cells (23, 24); a morphological study confirmed the occurrence of rapid binding of 
FVIIa to the endothelium and transfer into the extravascular space, where it is likely to bind to 
tissue factor (TF) on the pericytes (25). Through these mechanisms, rFVIIa could remain 
protected from degradation and, eventually, trigger further generation of thrombin. These cell-
based studies provide strong support for our main findings, namely the very large volume of 
distribution, low IVR and residual clotting activity when FVII:C is no longer detectable (Fig. 2). In 
the recent PK study conducted by Mathijssen et al. (10) a large volume of distribution for rFVIIa 
was also reported and the authors suggested that this finding could explain the prolonged 
prophylaxis effect and here we provide some clotting-related evidence to this hypothesis. 
 
Mathijssen and colleagues also found that the FVII antigen circulated for a longer time than 
FVIIa (12) a finding confirmed by their more recent study on PK in FVII deficiency (10). As FVII 
antigen does not account for clotting activity, this introduces the question related to what is the 
most convenient assay for evaluating the PK features of rFVIIa. This issue was also addressed 
by Scharling et al. (26), who compared FVII:C with a FVIIa functional assay, showing that the 
latter was characterised by less variable PK features and more reliable results, especially when 
assessing low FVII activity levels (<2–3%). To further contribute to this clinically relevant issue, 
we compared the kinetics of FVII:C to that of PTr. Data were highly comparable (Table 2) with 
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data obtained from both assays displaying a very good correlation with time (1/PTr ‘r’ = -0.98 
and FVII:C ‘r’ = -0.99). Using the PTr, PK parameters were characterised by a very slow 
clearance (about one-quarter of that obtained using FVII:C), a four-times larger AUC and a 
much longer t1/2 (Fig. 2), differences that were all highly significant (all p<0.001). However, there 
are methodological aspects important to consider when interpreting these results; while the PTr 
examines an individual’s TF pathway as a whole, including the patient’s accelerators and 
inhibitors, the FVII:C assay largely depends on exogenous factors and co-factors provided by 
the FVII-deficient plasma, very prevalent (at least 10 times) in the assay. This may account for 
the very different PK results obtained using the two methods, and suggests a potential role for 
soluble plasma factors. Hence, the FVII:C-based findings may only partially represent the in vivo 
pro-coagulant potential and therefore provide a poor prediction of efficacy.  
 
A limitation of this study is that the protocol used was limited to a 24-hour observation period, 
and therefore we did not record the tail of the PTr curve (Fig. 2). In fact, more than 20% of the 
‘clotting potential’ examined using the PTr was still present 24 hours after rFVIIa infusion, when 
FVII:C was no longer detectable. The prolonged clotting correction provided by rFVIIa (as 
detected by the PTr) is in agreement with the observation by Brummel Ziedins (27). 
 
In conclusion, our data support previous convincing clinical data (11-14) published on the 
efficacy of prophylaxis in FVII deficiency, and provides evidence for a large volume of 
distribution of rFVIIa and the persistence of a clotting potential when FVII:C is no longer 
detectable. The rapid and substantial diffusion of rFVIIa towards the extravascular spaces would 
trigger a yet unexplored mechanism to provide pro-coagulant activity for a longer time than 
expected.  
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Legends to Figures and Tables 
Figure 1: Comparison between IVR obtained in individuals with different clinical 
phenotypes.  
Figure 2: Comparison between the FVII plasma concentration following the infusion of 
rFVIIa in patients with severe FVII deficiency (n=10) using data obtained from either the 
FVII:C or PTr. The solid lines represent the means, and the dashed lines represent the variance 
(1 SD). Comparison between IVR obtained in individuals with different clinical 
phenotypes. 
Table 1: Demographic and clinical data (STER cohort) 
Table 2: Kinetic parameters calculated using FVII:C levels (N=10) and 1/PTR (mean values 
only of dose-independent parameters) 
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Table 1. Demographic and clinical data (STER cohort) 
Demographic data (N=56)  
Age (years) 
Mean (SD), median (range) 
 
32.8 (24.2), 23 (281) 
Weight (kg) 
Mean (SD), median (range) 
 
58.3 (23.7), 60 (11110) 
FVII:C level (%) 
Mean (SD), median (range) 
 
7.6 (8.6), 4 (<126) 
Sex (F/M) 32/24 
Asymptomatic, n (%) 
Symptomatic, n (%) 
 Major bleeders 
 Minor bleeders 
19 (33.9) 
37 (66.1) 
12 (21.4) 
25 (44.6) 
Clinical data  
Bleeding type, frequency (%)  
 Menorrhagia 33.90 
 Epistaxis 32.10 
 Gum bleeding 28.60 
 Bruising 28.60 
 Muscle haematoma and subcutaneous haematoma 28.60 
 Haemarthrosis 17.90 
 Other symptoms 17.90 
 Haemoperitoneum 12.50 
 Post-operative bleeding 8.90 
 Haematuria 7.10 
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 Haemorrhoidal bleeding 7.10 
 Gastrointestinal bleeding 3.60 
 Central nervous system bleeding 1.80 
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Table 2. Kinetic parameters calculated using FVII:C levels and 1/PTR (mean values only 
of dose-independent parameters) 
 
AUClast, area under the plasma concentrationtime curve from time zero to the last measurable 
concentration; AUMClast, area under the moment curve from time zero to the last measurable 
concentration; CLobs, clearance; HL  z, terminal phase half-life; I-IVR, incremental in vivo 
recovery; lambda () z, terminal elimination rate constant; MRTlast, mean residence time from 
time zero to the last measurable concentration; t1/2, distribution phase half-life; Vssobs, apparent 
volume of distribution at equilibrium; P-IVR, percentage IVR; Vzobs, apparent volume of 
distribution during the terminal phase. 
 FVII:C    1/PTr  
Parameter Mean SD Min Max Mean p 
Correlation XY (r) 0.99 0.01 1.00 0.98 0.98  
Number of points  z 3.80 1.32 3.00 6.00 6.22 <0.001 
Lambda () z (1/hours) 0.20 0.07 0.06 0.33 0.06 <0.001 
HL  z (hours) 4.23 2.58 2.10 11.15 13.81 <0.001 
AUClast (U*h dl
-1) 218.84 27.46 183.18 267.55 -----  
Vzobs (dl kg
-1) 24.98 8.86 14.48 42.12 ------  
CLobs (dl h kg
-1) 4.41 0.72 2.62 5.07 ------  
AUMClast (U*h
2 l-1) 681.87 252.20 494.37 1324.16 ------  
MRTlast (hours) 3.05 0.72 2.37 4.95 8.38 <0. 001 
Vssobs (dl kg
-1) 14.72 3.83 11.36 25.02 ------  
t1/2 (hours) 2.12 0.50 1.64 3.44 5.80 <0.001 
I-IVR (U dl-1/U kg-1) 0.57 0.28 0.12 1.02 ------  
P-IVR (%) 25.33 12.47 5.4 45 ------  
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Extra Table 
What is known on this topic: 
 rFVIIa has a very short half-life and rapid clearance 
 rFVIIa rapidly diffuses towards the extravascular spaces 
 rFVIIa is effectively used for prophylaxis in FVII deficiency 
What this paper adds: 
 rFVIIa has a low ex vivo Recovery 
 Ex vivo recovery is independent of age and sex 
 Ex vivo recovery is higher in major bleeders  
 rFVIIa has a very large volume of distribution at the steady state 
 The PTr-related kinetic data demonstrate that there is a considerable clotting potential 
available when FVII:C levels are no longer detected in the bloodstream 
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Figure 1.  
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Figure 2.  
 
 
 
 
